Literature DB >> 27424878

Heterogeneity and antibiotic resistance in Propionibacterium acnes isolates and its therapeutic implications: blurring the lines between commensal and pathogenic phylotypes.

Suresh Sadhasivam1,2, Mau Sinha1, Swamini Saini1, Simar Preet Kaur1, Tanvi Gupta3, Shiladitya Sengupta4,5, Shamik Ghosh1, Kabir Sardana3.   

Abstract

Acne vulgaris is a multifactorial skin disease associated with the colonization of Propionibacterium acnes. Antibiotics are a mainstay of treatment for acne, yet the emergence of resistance against the currently approved antibiotics is a serious concern. In this case report, a slow responder had multiple Propionibacterium acnes isolates with varied levels of sensitivity to the conventional antibiotics. The bacterial isolates obtained from acne samples collected from the patient were analyzed for phylogeny, and was found to be largely restricted to two different lineage patterns. Propionibacterium acnes phylotype IA1, which is considered to be pathogenic, displayed clindamycin sensitivity, but phylotype IB, which is associated with commensals, exhibited high clindamycin resistance. Sensitivity analysis revealed uniform resistance to macrolides, but susceptibility to tetracycline and nadifloxacin. These results implicate Propionibacterium acnes in the pathophysiology of acne vulgaris, although the lines between commensal and pathological phylotypes may be blurred. Switching the patient to a combination of minocycline and nadifloxacin resulted in a significant improvement in the clinical lesions. Such a science-driven judicious selection of antibiotics can minimize the probability of development of resistance, and might be the way forward in the treatment of acne.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Propionibacterium acnes; antibiotic resistance; clindamycin; commensal; phylotype

Mesh:

Substances:

Year:  2016        PMID: 27424878     DOI: 10.1111/dth.12391

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  4 in total

1.  Development of a topical bacteriophage gel targeting Cutibacterium acnes for acne prone skin and results of a phase 1 cosmetic randomized clinical trial.

Authors:  M Golembo; S Puttagunta; U Rappo; E Weinstock; R Engelstein; I Gahali-Sass; A Moses; E Kario; E Ben-Dor Cohen; J Nicenboim; H Ben David; K Sudakov; A Cohen; M Bassan; N B Zak
Journal:  Skin Health Dis       Date:  2022-01-28

2.  Draft Genome Sequence of an Erythromycin-Resistant Propionibacterium acnes Isolate Recovered from Folliculitis of the Scalp.

Authors:  Guillaume Ghislain Aubin; Stanimir Kambarev; Aurélie Guillouzouic; Amir Khammari; Brigitte Dréno; Stéphane Corvec
Journal:  Genome Announc       Date:  2017-01-26

3.  Draft Genome Sequence of Methylocaldum sp. Strain 14B, an Obligate Hydrogen Sulfide-Tolerant Methanotrophic Strain That Can Convert Biogas to Methanol.

Authors:  Xiangdong Wei; Xumen Ge; Yebo Li; Zhongtang Yu
Journal:  Genome Announc       Date:  2017-04-20

4.  Efficacy and Safety of VB-1953 Topical Gel in Non-Responder Acne Patients with Clindamycin-Resistant Cutibacterium acnes.

Authors:  Rohit Batra; Suresh Sadhasivam; Swamini Saini; Swati Gupta; Rahul Kumar Singh Bisen; Mau Sinha; Shamik Ghosh; Shilpi Jain
Journal:  Drugs R D       Date:  2020-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.